The gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $81.3 million. In addition, Vogenx has granted the underwriters a 45-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is being made only by means of a prospectus forming part of the registration statement relating to these securities. These statements include, but are not limited to, statements relating to the anticipated size of the initial public offering and the expected trading commencement and closing dates. The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words.